Defective alterations in the collagen network to prostacyclin in COPD lung fibroblasts
Authors:
- Anna-Karin Larsson-CallerfeltALAnna-Karin Larsson-Callerfelt
- Oskar HallgrenOHOskar Hallgren
- Annika Andersson-SjölandAAAnnika Andersson-Sjöland
- Lena ThimanLTLena Thiman
- Johan BjörklundJBJohan Björklund
- Josefine KronJKJosefine Kron
- Kristian NihlbergKNKristian Nihlberg
- Leif BjermerLBLeif Bjermer
- Claes-Göran LöfdahlCLClaes-Göran Löfdahl
- Gunilla Westergren-ThorssonGWGunilla Westergren-Thorsson
Open Access
- 1 January 2013
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 14 (1) , 21
Abstract
Prostacyclin analogs are potent vasodilators and possess anti-inflammatory properties. However, the effect of prostacyclin on extracellular matrix (ECM) in COPD is not well known. Collagen fibrils and proteoglycans are essential ECM components in the lung and fibroblasts are key players in regulating the homeostasis of ECM proteins. The aim was to study the synthesis of prostacyclin and its effect on fibroblast activity and ECM production, and in particular collagen I and the collagen-associated proteoglycans biglycan and decorin. Parenchymal lung fibroblasts were isolated from lungs from COPD patients (GOLD stage IV) and from lungs and transbronchial biopsies from control subjects. The prostacyclin analog iloprost was used to study the effect of prostacyclin on ECM protein synthesis, migration, proliferation and contractile capacity of fibroblasts. TGF-β1 stimulation significantly increased prostacyclin synthesis in fibroblasts from COPD patients (p < 0.01), but showed no effect on fibroblasts from control subjects. Collagen I synthesis was decreased by iloprost in both control and COPD fibroblasts (p < 0.05). Conversely, iloprost significantly altered biglycan and decorin synthesis in control fibroblasts, but iloprost displayed no effect on these proteoglycans in COPD fibroblasts. Proliferation rate was reduced (p < 0.05) and contractile capacity was increased in COPD fibroblasts (p < 0.05) compared to control fibroblasts. Iloprost decreased proliferative rate in control fibroblasts (p < 0.05), whereas iloprost attenuated contraction capacity in both COPD (p < 0.01) and control fibroblasts (p < 0.05). Iloprost reduced collagen I synthesis and fibroblast contractility but did not affect the collagen-associated proteoglycans or proliferation rate in fibroblasts from COPD patients. Enhanced prostacyclin production could lead to improper collagen network fibrillogenesis and a more emphysematous lung structure in severe COPD patients.Keywords
This publication has 52 references indexed in Scilit:
- Enhanced ROCK1 dependent contractility in fibroblast from chronic obstructive pulmonary disease patientsJournal of Translational Medicine, 2012
- Glucocorticosteroids Differentially Regulate MMP-9 and Neutrophil Elastase in COPDPLOS ONE, 2012
- Stage-dependent association of BDNF and TGF-beta1 with lung function in stable COPDRespiratory Research, 2012
- Altered fibroblast proteoglycan production in COPDRespiratory Research, 2010
- A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in miceRespiratory Research, 2010
- Decorin Core Protein (Decoron) Shape Complements Collagen Fibril Surface Structure and Mediates Its BindingPLOS ONE, 2009
- Smad gene expression in pulmonary fibroblasts: indications for defective ECM repair in COPDRespiratory Research, 2008
- Lung Fibroblast Repair Functions in Patients with Chronic Obstructive Pulmonary Disease Are Altered by Multiple MechanismsAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Prostacyclin Analogs Inhibit Fibroblast Contraction of Collagen Gels through the cAMP-PKA PathwayAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Effects of Transforming Growth Factor β and Interleukin-1β on Expression of Cyclooxygenase 1 and 2 and Phospholipase A2 mRNA in Lung Fibroblasts and Endothelial Cells in CultureBiochemical and Biophysical Research Communications, 1993